In the early stages, fatty liver may be asymptomatic, with most people unaware they have it. However, continued fat buildup ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...

Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non ... twin endpoints relating to inflammation resolution and fibrosis (scarring) despite only ...

While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...

PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...

NASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver, which can lead to fibrosis that impairs liver function. In a separate development ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Bile duct inflammation and scarring, known as cholangiopathies, can disrupt bile flow, leading to liver damage and ...